Literature DB >> 28455727

Perioperative considerations for patients with sickle cell disease: a narrative review.

Narjeet Khurmi1, Andrew Gorlin2, Lopa Misra2.   

Abstract

PURPOSE: Approximately 200,000 individuals worldwide are born annually with sickle cell disease (SCD). Regions with the highest rates of SCD include Africa, the Mediterranean, and Asia, where its prevalence is estimated to be 2-6% of the population. An estimated 70,000-100,000 people in the United States have SCD. Due to enhanced newborn screening, a better understanding of this disease, and more aggressive therapy, many sickle cell patients survive into their adult years and present more frequently for surgery. SOURCE: The authors identified relevant medical literature by searching PubMed, MEDLINE®, EMBASE™, Scopus™, Web of Science, and Google Scholar databases for English language publications appearing from 1972-September 2016. Case reports, abstracts, review articles, and original research articles were reviewed-with particular focus on the pathophysiology and medical management of SCD and any anesthesia-related issues. PRINCIPAL
FINDINGS: Perioperative physicians should be familiar with the triggers of a sickle cell crisis and vaso-occlusive disease. Sickle cell disease affects various organ systems, including the central nervous, cardiovascular, pulmonary, genitourinary, and musculoskeletal systems. Preoperative assessment should focus on end-organ dysfunction. Controversy continues regarding if and when sickle cell patients should receive transfusions and which anesthetic technique (regional or general) confers any benefits. Timely, appropriate, and sufficient analgesia is critical, especially when patients experience a vaso-occlusive crisis, acute chest syndrome, or acute postoperative pain.
CONCLUSION: Effective management of SCD patients in the perioperative setting requires familiarity with the epidemiology, pathophysiology, clinical manifestations, and treatment of SCD.

Entities:  

Mesh:

Year:  2017        PMID: 28455727     DOI: 10.1007/s12630-017-0883-3

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  3 in total

1.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

2.  Incidence of Post-Operative Complications and Factors Influencing Their Occurrence in Patients with Sickle Cell Disease in a Low-Income Country: A Case Study of Cameroon.

Authors:  Dominique Djomo Tamchom; Charlotte Eposse Ekoube; Basile Essola; Serge Nga Nomo; Fleur Samantha Benghiat; Luc Van Obbergh
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

3.  Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.

Authors:  Arianna Barbetta; Cameron Goldbeck; Angelina Lim; Sean P Martin; Jeffrey A Kahn; M Raashid Sheikh; Juliet Emamaullee
Journal:  HPB (Oxford)       Date:  2021-07-06       Impact factor: 3.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.